Tag Archives: Laidlaw Jen

Affimed (AFMD) Receives a Buy from Laidlaw

Laidlaw analyst Yale Jen reiterated a Buy rating on Affimed (NASDAQ: AFMD) on June 23 and set a price target of $10.00. The company’s shares closed last Friday at $3.81. Affimed has an analyst consensus of Moderate Buy, with a

Laidlaw Reiterates Buy on Affimed Shares, Sees 162% Upside For The Stock

In a research report published on Tuesday, Laidlaw analyst Yale Jen reiterated a Buy rating on Affimed (NASDAQ:AFMD)with a price target of $10, which implies an upside of 162% from current levels. According to TipRanks.com, which measures analysts’ and bloggers’

Laidlaw Reiterates Their Buy Rating on Ziopharm Oncology (ZIOP)

In a report issued on June 1, Yale Jen from Laidlaw reiterated a Buy rating on Ziopharm Oncology (NASDAQ: ZIOP), with a price target of $7.50. The company’s shares closed last Friday at $3.27. Currently, the analyst consensus on Ziopharm

Laidlaw Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)

In a report issued on May 13, Yale Jen from Laidlaw reiterated a Buy rating on Soleno Therapeutics (NASDAQ: SLNO), with a price target of $10.00. The company’s shares closed last Friday at $3.26. Soleno Therapeutics has an analyst consensus

Laidlaw Keeps a Buy Rating on Aldeyra Therapeutics (ALDX)

Laidlaw analyst Yale Jen reiterated a Buy rating on Aldeyra Therapeutics (NASDAQ: ALDX) on May 7 and set a price target of $30.00. The company’s shares closed last Tuesday at $4.11. Aldeyra Therapeutics has an analyst consensus of Strong Buy,